TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median time to symptomatic mania remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: a* value reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cross-sectional area (CSA) of internal jugular vein (IJV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overlap index between IJV and common carotid artery (CCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in panic symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: prostaglandin E(2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-free days per 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency department visits or hospitalization for asthma
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression‐Improvement scale score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMSE score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPI score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting FMD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: periprocedural pain
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: nighttime systolic/diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-year LTx-free survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of improvement of sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in plasma renin activity (PRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients reaching blood-pressure goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of TNF-alpha, IL-6, and IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity rates for serotype 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infarct growth attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight gain per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral content (BMC) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean mass (LM) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rapidity of choroidal filling in peripapillary regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Red blood cell count (RBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall self-assessment of competence in communication skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: composite end point of prolonged catecholamine infusion, use of left ventricular mechanical assist device, or renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in cognitive disorders
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in anxiety disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Flushing incidence and intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of vision loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen availability (DO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone turnover markers (BALP, CTx, osteocalcin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in knee-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean pain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSQ score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: inhospital mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Dose-dependent leukoneutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of E (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal bone thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lingual bone thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesial root changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ventilation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone markers (BAP, PINP, CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of insulin resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Written assessment of interpretation of therapy interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma glutamyl transferase (GGT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sternal wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: infection at a wound or catheter site
Endpoint domain: Adverse events/effects
Primary endpoint: all-cause death rate
Endpoint domain: Mortality/survival
Primary endpoint: slide review rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume daily activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting and postural tremor involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contrast enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased microbial richness and abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean daily food cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overweight and obesity prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended lifespan
Endpoint domain: Mortality/survival
Primary endpoint: D90 for high-risk PTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumes receiving 60 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross tumor volume doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy Outcome Measure Handicap
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: EQ‐5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Deterioration in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Macrovascular event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analogue Scale (VAS) pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily rescue analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Legal blindness within 5 years
Endpoint domain: Mortality/survival
Primary endpoint: mean reduction in whole mouth plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean TMQHPI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean brushing time increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cESS-corrected MWFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: εLs-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Categorical success rates for VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorical success rates for ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee joint stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rectus femoris activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: patients' satisfaction with home visit service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbiologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-reported quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesic frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Normalization of alanine transaminase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-limb pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Blood EtOH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood acetaldehyde concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Satisfaction with teeth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom-free status after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of treatment (SCM-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores for venipuncture pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Behavioral Distress scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma MICB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Granzyme A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QOL Face Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of nonfibrotic ILA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of fibrotic ILA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DUI arrest within 3 years of hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Risk of developing anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of developing iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uptake of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: muscle thickness atrophy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thigh circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in peak VO2/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to perform imaging behaviours
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Expansion in visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on ADLs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity of BresoDx-informed clinical diagnosis against PSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of BresoDx-informed clinical diagnosis against PSG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between clinical diagnosis informed by PSG versus BresoDx (Cohen's kappa coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of empathy rated by SPs and experts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to death or first nonfatal cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: haemostasis duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extension strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported physical function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with low back pain per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach EtO2≥90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spread of sensory and motor blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first PCA trigger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at resting (8h postoperatively)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at resting (24h postoperatively)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvements in executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pao2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Creatinine value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lactate value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of probable/proven invasive fungal infection (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: Fatality rate for Gram-negative bacteremia
Endpoint domain: Mortality/survival
Primary endpoint: Fatality rate for Gram-positive bacteremia
Endpoint domain: Mortality/survival
Primary endpoint: sCD40L serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interference of atacicept with heparin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in CRPS signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of patients with ventilator-associated pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Cost per quality adjusted life year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of nausea during the first 2 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Total PONV during the first 2 hours
Endpoint domain: Adverse events/effects
Primary endpoint: vigor-activity improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: job satisfaction improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Epinephrine peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total epinephrine exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-reactivity to parecoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms reported by workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive reflection performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Agility time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound healing complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: UL perimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day composite of death or MI
Endpoint domain: Mortality/survival
Primary endpoint: Objective binocular visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of conversion to open surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of positive comments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of negative comments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of distinct issues identified
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum markers of CRPC activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary N-acetyl-beta-D-glucosaminidase index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PSE stage improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms and CEAP clinical class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent reflux
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent varicose veins
Endpoint domain: Adverse events/effects
Primary endpoint: Mean HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak quadriceps strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak quadriceps and hamstring (Q:H) strength ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: passive knee stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disability index improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weeks of pain relief
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: reduction in carbohydrate intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of aeroallergen sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systolic blood pressure under 35% CO2 challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: psychological responses at VAAS, VAS‐F, VAS‐D, and PSL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in NRS pain scores post-TKR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rates of thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: mean methionine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response evaluation (mixed responses, stable disease, progression of disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell proliferation to allogeneic tumor cell stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of IL-4 and IL-5 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitation of OLZ in human plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscular fat content (MFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local CBF decrease in brainstem and thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marked improvement following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of allergen-specific IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ET-1 mediated vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to dissolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis
Endpoint domain: Mortality/survival